Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 7/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14346178 | 0.91 | CDK2 (0.44) | GSK3BCDK7CDK2CCNE1CCNH | |
| SCHEMBL14346391 | 0.91 | CDK2 (0.44) | GSK3BCDK7CDK2CCNE1CCNH | |
| SCHEMBL14364519 | 0.91 | CDK7 (0.40) | GSK3BCDK7CDK2CCNE1CCNH | |
| SCHEMBL14346508 | 0.91 | CDK7 (0.40) | GSK3BCDK7CDK2CCNE1CCNH | |
| SCHEMBL14346162 | 0.90 | CDK2 (0.40) | GSK3BCDK7CDK2CCNE1CCNH | |
| SCHEMBL14346165 | 0.90 | CDK2 (0.40) | GSK3BCDK7CDK2CCNE1CCNH | |
| SCHEMBL14346561 | 0.90 | CDK2 (0.40) | GSK3BCDK7CDK2CCNE1CCNH | |
| SCHEMBL14364520 | 0.90 | CDK2 (0.40) | GSK3BCDK7CDK2CCNE1CCNH | |
| SCHEMBL14346499 | 0.87 | GSK3B (0.43) | GSK3BCDK7CDK2CCNE1CCNH | |
| SCHEMBL14364537 | 0.84 | CDK2 (0.50) | GSK3BCDK7CDK2CCNE1CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007139732-A1 | PYRAZOLO [1, 5-A] PYRIMIDINES AS CDK INHIBITORS | SCHERING CORPORATION (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275963-A1 | PYRAZOLO[1,5-a]PYRIMIDINES | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070275963-A1 | PYRAZOLO[1,5-a]PYRIMIDINES | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275963-A1 | PYRAZOLO[1,5-a]PYRIMIDINES | CDK2, CDKN1A, CDK1 | GSK3B 1207/4885CDK7 11/4885CDK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.